七月 2026
- Home
- Clival Database
七月 2026的Clival Database市场份额分析
Alto Neuroscience has completed enrollment in its Phase 2 proof-of-concept trial evaluating ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor, for cognitive impairment associated with schizophrenia (CIAS).
Clival Database(包含公司地区分支机构)
查看更多网站流量和参与度信息- clival.com
Clival Database热门域名的总访问量
了解Clival Database市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Clival Database热门域名的平均访问时长
分析Clival Database参与度指标。
过去 3 个月的平均访问时长
子公司明细
Clival Database热门域名的平均页面浏览量
了解Clival Database如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Clival Database 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Clival partners with Emory Healthcare Hospital Group.Clival is thrilled to collaborate with Emory University, a leader in clinical research with a heritage of studying next-generation vaccines and cutting-edge technologies, and with the CDC, whose work to develop this novel vaccine and collaboration with Micron Biomedical to deliver it without needles has been ground-breaking.
六月 18, 2025阅读更多
新闻Clival launches Actimab-A solid tumour programme.Additionally, Clival has launched its Actimab-A solid tumour programme to combine with PD-1 checkpoint inhibitors Keytruda and Opdivo for patients with head and neck squamous carcinoma and non-small cell lung cancer in multiple trials.
三月 27, 2025阅读更多
新闻Clival launches combination therapy trial.Lifescience Intellipedia Pvt Ltd is therefore very excited to be launching this first combination therapy trial".
十一月 23, 2022阅读更多
查看 Clival Database 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
